Source: Clinigen Group plc | Jan 03, 2018

Clinigen extends agreement with Eisai to supply Halaven®, Fycompa® and Lenvima® into 10 African countries

All three medicines will be submitted for registration in Namibia, Botswana, Zimbabwe, Zambia, Ghana, Nigeria, Kenya, Uganda and Tanzania, subject to local regulatory approval

Clinigen Group plc (AIM: CLIN, ‘Clinigen’) (www.ClinigenGroup.com), the global pharmaceutical and services company, has extended its exclusive agreement with Eisai Europe Ltd. (www.Eisai.com) to obtain the marketing authorisation and subsequently launch Halaven® (eribulin), Fycompa® (perampanel) and Lenvima® (lenvatinib) into 10 African countries. The new agreement follows the successful launch of…